Key result
In patients without a history of mood disorders, angiotensin antagonist monotherapy was associated with a slightly increased risk of new-onset major depressive disorder (HR 1.17) but a reduced risk of bipolar disorder (HR 0.46).
Why the study?
Recent work suggests antihypertensive medications may be useful as repurposed treatments for mood disorders, prompting investigation into whether specific classes reduce the risk of new-onset MDD or bipolar disorder.
Do antihypertensive medications reduce the risk of new-onset major depressive disorder or bipolar disorder in patients treated for hypertension?
Cohort (n=1,852,793)
Do antihypertensive medications reduce the risk of new-onset major depressive disorder or bipolar disorder in patients treated for hypertension?
Hazard Ratio: 1.17 (95% CI 1.04–1.31)
Antihypertensive medications do not appear to prevent new episodes of major depressive disorder, but angiotensin antagonists may represent a novel repurposed treatment avenue for bipolar disorder.
Angiotensin antagonists warrant caution for incident depression in hypertension; leaves open repurposing for bipolar disorder prevention.
BACKGROUND: Recent work suggests that antihypertensive medications may be useful as repurposed treatments for mood disorders. Using large-scale linked healthcare data we investigated whether certain classes of antihypertensive, such as angiotensin antagonists (AAs) and calcium channel blockers, were associated with reduced risk of new-onset major depressive disorder (MDD) or bipolar disorder (BD). METHOD: Two cohorts of patients treated with antihypertensives were identified from Scottish prescribing (2009-2016) and hospital admission (1981-2016) records. Eligibility for cohort membership was determined by a receipt of a minimum of four prescriptions for antihypertensives within a 12-month window. One treatment cohort (n = 538 730) included patients with no previous history of mood disorder, whereas the other (n = 262 278) included those who did. Both cohorts were matched by age, sex and area deprivation to untreated comparators. Associations between antihypertensive treatment and new-onset MDD or bipolar episodes were investigated using Cox regression. RESULTS: For patients without a history of mood disorder, antihypertensives were associated with increased risk of new-onset MDD. For AA monotherapy, the hazard ratio (HR) for new-onset MDD was 1.17 (95% CI 1.04-1.31). Beta blockers' association was stronger (HR 2.68; 95% CI 2.45-2.92), possibly indicating pre-existing anxiety. Some classes of antihypertensive were associated with protection against BD, particularly AAs (HR 0.46; 95% CI 0.30-0.70). For patients with a past history of mood disorders, all classes of antihypertensives were associated with increased risk of future episodes of MDD. CONCLUSIONS: There was no evidence that antihypertensive medications prevented new episodes of MDD but AAs may represent a novel treatment avenue for BD.
No takes yet. Share an insight, caveat, or question.
Shaw et al. (2020) conducted a cohort in Mood disorders (Major depressive disorder and bipolar disorder) (n=1,852,793). Angiotensin antagonists vs. Untreated comparators was evaluated on New-onset major depressive disorder (MDD) (HR 1.17, 95% CI 1.04-1.31). In patients without a history of mood disorders, angiotensin antagonist monotherapy was associated with a slightly increased risk of new-onset major depressive disorder (HR 1.17) but a reduced risk of bipolar disorder (HR 0.46).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: